| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/03/2001 | US6211343 Lactoferrin receptor protein |
| 04/03/2001 | US6211243 Methods for treating cold sores with anti-infective compositions |
| 04/03/2001 | US6211222 Substituted indazole derivatives and related compounds |
| 04/03/2001 | US6211212 Drugs with amide and ester groups as enzyme inhibitors |
| 04/03/2001 | US6211208 2-aminopyridines containing fused ring substituents |
| 04/03/2001 | US6211170 Azetidinone derivatives for the treatment of HCMV infections |
| 04/03/2001 | US6211167 Arylsulfonanilide phosphates |
| 04/03/2001 | US6211162 Pulmonary delivery of protonated/acidified nucleic acids |
| 04/03/2001 | US6211161 UDP-N-acetylmuramoyl-l-alanine:D-glutamate ligase (MURD) of staphylococcus aureus |
| 04/03/2001 | US6211151 Peptides with organo-protective activity, a process for preparation thereof and their use in therapy |
| 04/03/2001 | US6211148 Antimicrobial peptides from bovine neutrophis |
| 04/03/2001 | US6211147 Method of promoting angiogenesis using relaxin |
| 04/03/2001 | US6210968 DNA molecules encoding pgp3 protein from Chlamydia trachomatis |
| 04/03/2001 | US6210944 Phosphoribosyl transferase from Staphylococcus aureus |
| 04/03/2001 | US6210903 Amino acid sequence which is optionally modified and biotinylated |
| 04/03/2001 | US6210685 Acellular whooping cough vaccines. |
| 04/03/2001 | US6210684 Method for delaying the onset of AIDS |
| 04/03/2001 | US6210682 Immunization against rotavirus infection or rotavirus disease by administering to a subject a peptide nsp4 114-135, a peptide nsp4 120-147, or a toxoid thereof are disclosed. |
| 04/03/2001 | US6210676 Compositions and methods using the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease |
| 04/03/2001 | US6210675 Post-transfusional non-a non-b hepatitis viral polypeptide |
| 04/03/2001 | US6210674 GreA from Staphylococcus aureus |
| 04/03/2001 | US6210673 gidB from Staphylococcus aureus |
| 04/03/2001 | US6210670 Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin |
| 04/03/2001 | US6210661 IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, and bacterial diseases and of fungal infections |
| 04/03/2001 | CA2200169C Triazole antifungal agents |
| 04/03/2001 | CA2102772C Azetidinone compound and process for preparation thereof |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/30/2001 | CA2283538A1 New hev antigenic peptide and methods |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021804A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 03/29/2001 | WO2001021800A1 Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus) |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021651A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021623A1 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof |
| 03/29/2001 | WO2001021622A1 Process for the preparation of 3-sulfonyloxy-3-cephem compounds |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021600A1 Caspase inhibitor |
| 03/29/2001 | WO2001021598A1 Therapeutic quinazoline compounds |
| 03/29/2001 | WO2001021591A1 Pyrazole derivatives |
| 03/29/2001 | WO2001021587A2 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors |
| 03/29/2001 | WO2001021583A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 03/29/2001 | WO2001021575A1 Anti-inflammatory nitro- and thia- fatty acids |
| 03/29/2001 | WO2001021210A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | WO2001021209A1 Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | WO2001021207A2 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021203A1 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration |
| 03/29/2001 | WO2001021201A2 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 03/29/2001 | WO2001021200A1 Oral recombinant lactobacilli vaccines |
| 03/29/2001 | WO2001021193A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | WO2001021189A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | WO2001021176A1 Methods of use of fluoroquinolone compounds against bacteria |
| 03/29/2001 | WO2001021175A1 Antibacterial medicinal compositions |
| 03/29/2001 | WO2001021172A1 Anti-cancer nitro- and thia-fatty acids |
| 03/29/2001 | WO2001021171A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021170A1 Systems for delivering anti-infective compositions from frangible ampules to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021169A1 Mch antagonists |
| 03/29/2001 | WO2001021156A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | WO2001021152A1 Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| 03/29/2001 | WO2001021151A1 Intranasal influenza virus vaccine |
| 03/29/2001 | WO2001020981A2 Anti-infective compositions for treating disordered tissue such as cold sores |
| 03/29/2001 | WO2001000612A3 Respiratory syncytial virus replication inhibitors |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000064939A3 Peptides derived from vasostatin i and the use thereof as anti-fungal agents |
| 03/29/2001 | WO2000061067A3 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 03/29/2001 | WO2000059875A3 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO2000012741A9 Inducible expression system |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945982A1 Geschwindigkeitsbestimmte Partikel Certain particle velocity |
| 03/29/2001 | DE19944767A1 N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel N-substituted 4-Aminopteridine, processes for their preparation and their use as medicaments |
| 03/29/2001 | DE19938767A1 Producing cleavage vaccines, especially influenza vaccines, of high immunogenicity, comprises cleaving a lipid capsule of virus particles using a fatty acid or its salt |
| 03/29/2001 | CA2391976A1 Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | CA2386767A1 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385479A1 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof |
| 03/29/2001 | CA2385447A1 Pyrazole derivatives |
| 03/29/2001 | CA2385404A1 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration |
| 03/29/2001 | CA2384829A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | CA2384806A1 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383589A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | CA2383433A1 Oral recombinant lactobacilli vaccines |
| 03/29/2001 | CA2383413A1 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | CA2383147A1 Mch antagonists |
| 03/29/2001 | CA2383110A1 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| 03/29/2001 | CA2377525A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | CA2369515A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | CA2351673A1 Pharmaceutical antibacterial compositions |
| 03/29/2001 | CA2319213A1 Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof |
| 03/28/2001 | EP1087014A1 Hog cholera virus vaccine and diagnostic |
| 03/28/2001 | EP1087013A2 Immunoglobulins devoid of light chains |
| 03/28/2001 | EP1086695A1 Antiviral compositions comprising yohimbine as active principle |
| 03/28/2001 | EP1086690A2 Pharmaceutical formulations of cefaclor |
| 03/28/2001 | EP1086689A2 Pharmaceutical formulations of cefaclor |
| 03/28/2001 | EP1086252A1 Herpes simplex virus origin binding protein n-terminal truncation (obp-nt) |